Loading...

ACHV ACHIEVE LIFE SCIENCES INC Capital Structure Changes 8-K Filing

CHV

CHV

ACHIEVE LIFE SCIENCES INC

(ACHV)

2026 8-K

Management Changes

Stock Issuance Agreement

Financial Results

Third Quarter Results

Management Change

Management Change

Earnings Releases

Equity Offerings

Financial Statements

Financial Results

Management Change

Q3 Financial Results

Q2 Financial Results

Refinancing of Term Loans

Financial Results Announcement

Financial Results Announcement

Securities Purchase Agreeme...

FDA Update on Cytisinicline...

Earnings Reports

Earnings Reports

Securities Purchase Agreement

Debt Agreement and Converti...

Earnings Reports

External Links:

Achieve Life Sciences, Inc. announced on April 15, 2026, it will sell 49,418,069 shares of common stock and warrants for an expected $180 million to fund its clinical trial for cytisinicline, following the departure of CEO Richard Stewart and the appointment of Andrew Goldberg as his successor.

AI Assistant

ACHIEVE LIFE SCIENCES INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.